In short
Clinical trials investigating Anastrozole are studying how it fits into treatment plans for different cancers, especially breast cancer. These studies look at treatment benefit, safety, and the best way to use it in specific patient groups such as early, advanced, premenopausal, and postmenopausal patients.
Key points
- Clinical trials with Anastrozole are mainly focused on breast cancer, especially hormone receptor-positive and HER2-negative disease. Most studies are Phase 3, with some Phase 2 and low-intervention trials, and they include early, advanced, premenopausal, postmenopausal, and older patient groups. Several trials compare Anastrozole with other endocrine therapies, while others study it with chemotherapy, CDK4/6 inhibitors, or new hormone treatments. The main outcomes are invasive breast cancer-free survival, disease-free survival, progression-free survival, recurrence, and overall survival. Some studies also look at tumor response, Ki-67 changes, quality of life, or drug distribution in tumor tissue. A few non-breast cancer studies also include Anastrozole in hormone-related cancers such as low-grade serous ovarian cancer and low-grade endometrial stromal sarcoma.
Overview of the Anastrozole trial program
These trials study Anastrozole in many cancer settings, with most work focused on breast cancer. The studies ask whether Anastrozole should be used alone, compared with other endocrine therapy, or combined with other treatments such as chemotherapy, CDK4/6 inhibitors, or newer hormone drugs. Most trials are in Phase 3, and a smaller number are in Phase 2 or low-intervention designs.
Breast cancer studies
Most Anastrozole trials involve early breast cancer, especially HR-positive/HER2-negative disease, which means the cancer responds to hormones but does not have high HER2 levels. Some studies focus on premenopausal patients, while others include postmenopausal patients, older adults, or people with node-positive disease, which means cancer has spread to lymph nodes.
Several trials compare Anastrozole with other endocrine treatments such as letrozole, exemestane, tamoxifen, or newer agents like elacestrant, camizestrant, giredestrant, and imlunestrant. In some studies, Anastrozole is part of a larger treatment strategy that also includes chemotherapy or targeted drugs such as ribociclib, palbociclib, abemaciclib, or giredestrant-related regimens.
Important breast cancer trials in the data include a large Phase 3 study in premenopausal patients with high-risk early breast cancer, a Phase 3 study comparing sequential versus concurrent chemotherapy and aromatase inhibitors, and several large trials in early breast cancer that measure invasive breast cancer-free survival or disease-free survival.
Other breast cancer studies look at more specific groups, such as patients with detectable ctDNA, which means small cancer-related DNA fragments found in the blood, or patients with ESR1 mutation, a genetic change linked to treatment resistance in some studies. Some trials also study advanced or metastatic disease, including patients with high tumor burden, visceral metastases, or HER2-low disease.
Other conditions studied
Although breast cancer is the main focus, Anastrozole also appears in trials for other hormone-sensitive cancers. One Phase 3 study includes low-grade serous ovarian or peritoneal carcinoma and compares maintenance letrozole alone with paclitaxel/carboplatin followed by letrozole, with Anastrozole listed among the hormone therapy options in the trial record. Another Phase 2 trial studies locally advanced or metastatic low-grade endometrial stromal sarcoma and compares stopping versus continuing aromatase inhibitors, including Anastrozole.
Study designs, phases, and who can join
Most of the studies are interventional, which means researchers assign participants to a treatment plan and then measure the results. The trial groups often include patients with early breast cancer, advanced breast cancer, or metastatic breast cancer, and some studies are limited to postmenopausal women, premenopausal women, men, or older adults.
Some trials have very large enrollment numbers, such as studies with more than 4,000 participants, while others are small, such as a 40-person tissue distribution study or a 67-person hot flash study. This shows that Anastrozole is being studied both in broad treatment trials and in smaller focused projects that ask a more specific question.
The data also include a window-of-opportunity study, which is a short study done before surgery to see how a treatment affects the tumor over a brief time. In that trial, the main measure was change in Ki-67 between the first tumor biopsy and a second biopsy after treatment.
Main endpoints being measured
The most common endpoint is invasive breast cancer-free survival, often shortened to IBCFS, which counts events such as invasive recurrence in the breast or nearby area, distant recurrence, a new cancer in the other breast, or death from any cause. Another very common endpoint is disease-free survival, which measures the time until cancer returns, a new cancer appears, or death occurs.
Some advanced breast cancer studies use progression-free survival (PFS), which is the time until the cancer gets worse or the patient dies. Other studies measure overall survival, distant metastasis-free survival, distant recurrence-free interval, relapse-free survival, or invasive disease-free survival, depending on the study question.
Some trials also measure patient-reported outcomes, which are answers patients give about symptoms or quality of life, and some measure tumor biology, such as Ki-67 or drug concentration inside tumor tissue using mass spectrometry. A few studies also track hot flashes, safety, tolerability, and serious adverse events when those are part of the research question.
What these trials may mean for patients
For patients, these studies show that Anastrozole is being tested in many different ways, not just as a single treatment but also as part of treatment plans that may be shorter, longer, combined, or switched with other therapies. The trial goals are mostly about lowering the chance of recurrence, delaying progression, and finding the best treatment sequence for different risk groups.
Some studies focus on people with very low-risk disease and ask whether treatment can be reduced, while others focus on high-risk disease and ask whether treatment should be intensified. This means the research is trying to match treatment intensity to the patient’s risk level and cancer type.